TBPH vs PRGO vs JNJ vs HLN

For growth investors, Theravance Biopharma, Inc.

(TBPH) is the stronger pick with 12. 1% revenue growth year-over-year, versus -4. 0% for Haleon plc (HLN). Haleon plc (HLN) offers the better valuation at 19. 0x trailing P/E (22. 2x forward), making it the more compelling value choice. Analysts rate Johnson & Johnson (JNJ) a "Buy" — based on 40 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Haleon plc (HLN) is the cheapest at 19.

0x versus Johnson & Johnson at 38. 4x. On forward P/E, Perrigo Company plc is actually cheaper at 5. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Haleon plc wins at 2. 63x versus Johnson & Johnson's 34. 17x.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +46.

1%, compared to -60. 1% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: JNJ returned +132. 3% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

06β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 1972% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Theravance Biopharma, Inc. (TBPH) carries a lower debt/equity ratio of 28% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Theravance Biopharma, Inc.

(TBPH) is pulling ahead at 12. 1% versus -4. 0% for Haleon plc (HLN). On earnings-per-share growth, the picture is similar: Haleon plc grew EPS 12. 5% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, TBPH leads at 5. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Johnson & Johnson (JNJ) is the more profitable company, earning 15.

8% net margin versus -87. 6% for Theravance Biopharma, Inc. — meaning it keeps 15. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24. 9% versus -72. 9% for TBPH. At the gross margin level — before operating expenses — TBPH leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Haleon plc (HLN) is the more undervalued stock at a PEG of 2. 63x versus Johnson & Johnson's 34. 17x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Perrigo Company plc (PRGO) trades at 5. 6x forward P/E versus 22. 2x for Haleon plc — 16. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

In this comparison, PRGO (9.

8% yield), JNJ (2. 2% yield), HLN (1. 9% yield) pay a dividend. TBPH does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

06), 2. 2% yield, +132. 3% 10Y return). Both have compounded well over 10 years (JNJ: +132. 3%, TBPH: -8. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TBPH is a small-cap quality compounder stock; PRGO is a small-cap income-oriented stock; JNJ is a large-cap quality compounder stock; HLN is a mid-cap quality compounder stock. PRGO, JNJ, HLN pay a dividend while TBPH does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.